tbuckley/cabot-search huggingface dataset:
Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2<sup>+</sup>/HER2<sup>– </sup>advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study.
Authors: Manish A. Shah, Jaffer A. Ajani, Salah-Eddin Al-Batran, Yung-Jue Bang, Daniel V.T. Catenacci, Peter C. Enzinger, David H. Ilson, Sunnie S. Kim, Florian Lordick, Kohei Shitara, Eric Van Cutsem, Ahsan Arozullah, Jeffrey J. Raizer, Jung Wook Park, Rui-hua Xu
Journal: Journal of Clinical Oncology (2022)

TPS365 Background: Despite standard treatment options (eg, CAPOX, capecitabine + oxaliplatin), 5-year survival with advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) is poor and limited biomarkers exist to inform treatment selection. Claudin 18.2 (CLDN18.2), a targetable biomarker, is a tight junction protein that is normally confined to gastric mucosa of healthy tissue and is often retained in G/GEJ. Zolbetuximab, a chimeric IgG1 monoclonal antibody, binds to CLDN18.2 and mediates cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Phase 2 (FAST; Sahin, Ann Oncol. 2021) results showed prolonged survival with zolbetuximab + EOX (epirubicin, oxaliplatin, capecitabine) vs EOX in CLDN18.2 + advanced G/GEJ. Preliminary phase 2 (NCT03505320, ILUSTRO Cohort 2; Klempner, J Clin Oncol. 2021) results showed promising antitumor activity with combination zolbetuximab + mFOLFOX6 (5-fluorouracil, folinic acid, oxaliplatin) in CLDN18.2 + advanced G/GEJ. Methods: GLOW (NCT03653507) is enrolling ̃500 adults from global sites. Patients are required to have radiologically evaluable (RECIST v1.1) CLDN18.2 + /HER2 – locally advanced unresectable or metastatic G/GEJ. Prior chemotherapy for advanced/metastatic G/GEJ is not permitted. Patients will be randomized 1:1 to zolbetuximab + CAPOX or placebo + CAPOX. Randomization will be stratified by region (Asia vs non-Asia), number of metastatic sites (0 to 2 vs ≥3), and prior gastrectomy (yes vs no). Zolbetuximab will be administered at 800 mg/m 2 IV on Cycle 1 Day 1 (loading dose), then at 600 mg/m 2 IV every 3 weeks; 8 cycles of CAPOX will be administered. Central testing of tumor tissue will determine CLDN18.2 status; tumors will be considered CLDN18.2 + if ≥75% of tumor cells show moderate to strong membranous immunohistochemical staining. Primary endpoint: progression-free survival per independent review. Secondary endpoints: overall survival; objective response rate; duration of response; safety/tolerability, pharmacokinetics, and immunogenicity of zolbetuximab. As of September 22, 2021, 135 sites were open for screening and enrollment. Clinical trial information: NCT03653507.
The Propaganda for Reform
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association of serum 25-hydroxyvitamin D concentrations with risk of dementia among individuals with type 2 diabetes: A cohort study in the UK Biobank
Authors: Tingting Geng, Qi Lu, Zhenzhen Wan, Jingyu Guo, Liegang Liu, An Pan, Gang Liu
Journal: PLoS Medicine (2022)

Several epidemiological studies have suggested that vitamin D status is associated with risk of dementia in general populations. However, due to the synergistic effect between diabetic pathology and neuroinflammation, and the prothrombotic profile in patients with diabetes, whether vitamin D is associated with risk of dementia among patients with diabetes is unclear. This study aimed to investigate the associations of circulating vitamin D levels with risks of all-cause dementia, Alzheimer disease (AD), and vascular dementia (VD) among adults with type 2 diabetes (T2D).This study included 13,486 individuals (≥60 years) with T2D and free of dementia at recruitment (2006-2010) from the UK Biobank study. Serum 25-hydroxyvitamin D (25[OH]D) concentrations were measured using the chemiluminescent immunoassay method at recruitment. Serum 25(OH)D ≥ 75 nmol/L was considered sufficient, according to the Endocrine Society Clinical Practice Guidelines. Incidence of all-cause dementia, AD, and VD cases was ascertained using electronic health records (EHRs). Each participant's person-years at risk were calculated from the date of recruitment to the date that dementia was reported, date of death, date of loss to follow-up, or 28 February 2018, whichever occurred first. Among the 13,486 individuals with T2D (mean age, 64.6 years; men, 64.3%), 38.3% had vitamin D ≥ 50 nmol/L and only 9.1% had vitamin D ≥ 75 nmol/L. During a mean follow-up of 8.5 years, we observed 283 cases of all-cause dementia, including 101 AD and 97 VD cases. Restricted cubic spline analysis demonstrated a nonlinear relationship between serum 25(OH)D and risk of all-cause dementia (Pnonlinearity < 0.001) and VD (Pnonlinearity = 0.007), and the nonlinear association reached borderline significance for AD (Pnonlinearity = 0.06), with a threshold at around a serum 25(OH)D value of 50 nmol/L for all the outcomes. Higher serum levels of 25(OH)D were significantly associated with a lower risk of all-cause dementia, AD, and VD. The multivariate hazard ratios and 95% confidence intervals for participants who had serum 25(OH)D ≥ 50 nmol/L, compared with those who were severely deficient (25[OH]D < 25 nmol/L), were 0.41 (0.29-0.60) for all-cause dementia (Ptrend < 0.001), 0.50 (0.27-0.92) for AD (Ptrend = 0.06), and 0.41 (0.22-0.77) for VD (Ptrend = 0.01). The main limitation of the current analysis was the potential underreporting of dementia cases, as the cases were identified via EHRs.In this study, we observed that higher concentrations of serum 25(OH)D were significantly associated with a lower risk of all-cause dementia, AD, and VD among individuals with T2D. Our findings, if confirmed by replication, may have relevance for dementia prevention strategies that target improving or maintaining serum vitamin D concentrations among patients with T2D.
Metoclopramide Nasal Spray (Gimoti) for Diabetic Gastroparesis
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The incidence of pediatric cardiomyopathy: The prospective pediatric cardiomyopathy registry Steven E. Lipshultz, Lynn A. Sleeper, Jeffrey A. Towbin, April M. Lowe, E. John Orav, Gerald F. Cox, Paul R. Lurie, Kristina L. McCoy, Jane E. Messere, Rebecca A. Orfaly, Steven D. Colan. University of Rochester, Rochester, NY, New England Research Institutes, Watertown, MA
Journal: Journal of the American College of Cardiology (2001)
First prototype of a 4 French 180 degree side-viewing infrared fiber optic catheter for thermal imaging of atherosclerotic plaque Morteza Naghavi, Peter Melling, Khawar Gul, Mohammad Madjid, James T. Willerson, Ward Casscells. University of Texas-Houston, Houston, TX, Remspec Inc., Boston
Journal: Journal of the American College of Cardiology (2001)
Prospective evaluation of the point-of-care use of a rapid antigenic SARS-CoV-2 immunochromatographic test in a paediatric emergency department
Authors: Quentin Ollier, Sylvie Pillet, Olivier Mory, Julie Gagnaire, Charlotte Thuiller, Nadine Annino, Amandine Gagneux-Brunon, Elisabeth Botelho-Nevers, Thomas Bourlet, Bruno Pozzetto, Aymeric Cantais
Journal: Clinical Microbiology and Infection (2022)

This study aimed to evaluate the immunochromatographic coronavirus disease 2019 (COVID-19) speed antigen test (BioSpeedia, France) as an antigen point-of-care test (AgPOCT) to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at the paediatric emergency department of the University Hospital of Saint-Etienne in France. Between 15 January and 28 May, 2021, children presenting with respiratory symptoms compatible with COVID-19 infection (symptomatic group) or those requiring hospitalization for any reason (asymptomatic group) were included prospectively and received a nasopharyngeal aspiration to carry out both AgPOCT and quantitative reverse transcription (RT) PCR (RT-qPCR) tests, with the latter being used as the reference standard, for the diagnosis of SARS-CoV-2 infection. Among the 1009 enrolled children, we obtained a result from both techniques for 990: 33 (3.3%) tested positive with AgPOCT and 46 (4.6%) with RT-qPCR. The overall sensitivity and specificity of the AgPOCT were 69.6% (95% confidence interval (CI), 54.3-82.3) and 99.9% (95% CI, 99.4-100), respectively, compared with the RT-qPCR. Sensitivity increased to 82.9% (95% CI, 66.4-93.4) in symptomatic children. The mean cycle threshold value was significantly lower in positive samples for AgPOCT than in negative samples in the overall population and in both the symptomatic and asymptomatic groups. The use of the COVID-19 speed antigen test at the bedside in the emergency department has satisfactory performance for diagnosing SARS-CoV-2 infection in symptomatic children.
Models of the physician-patient relationship
Authors: L. Tibbles
Journal: JAMA (1992)

<h3>In Reply.</h3> —Defining the deliberative model as the paradigmatic physician-patient relationship serves heuristic and normative functions. For instance, the ideal guides physicians when they are uncertain; it also provides the shared assumptions and standards for physicians, patients, and society in general when evaluating medical practices. Nevertheless, just as physicians recognize that there is optimal clinical care for a particular disease and that deviation may be appropriate in particular clinical circumstances and for particular patients, so too there is an optimal physician-patient relationship and deviation from it may be appropriate in certain circumstances. As we stated, "Under different clinical circumstances [such as emergencies] different models may be appropriate.... [These deviations] would not be automatically condemned, but would require justification based on the circumstances of the clinical situation." These comments should make it clear that we agree with Drs Devereux and Silber, Mr Firlik, and Ms Schreiber. The best physician-patient relationship is
ETIOLOGY OF MUMPS
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P330: Chronic Kidney Disease is Associated With Short-Term Risk of Hospitalization Among Older Adults
Authors: Eugenia Wong, Shoshana H Ballew, Natalie Daya, Junichi Ishigami, Casey M Rebholz, Kunihiro Matsushita, Morgan Grams, Josef Coresh
Journal: Circulation (2018)

Background: Chronic kidney disease (CKD) is now staged by estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (ACR). Risks of cardiovascular disease, dialysis, and mortality are well described, but risks of hospitalization at older age have not been explored to the same depths. Hypothesis: CKD stages will be associated with risk of all-cause hospitalizations. Methods: The analysis was conducted on 5669 white and African-American participants of the ARIC Visit 5 (2011-2013) cohort (mean age, 76 y; female, 57%; African-American, 23%). CKD was staged according to KDIGO 2012 criteria with eGFR from serum cystatin C (eGFRcys) and ACR. The primary outcome of all-cause hospitalization risk was analyzed by using negative binomial regression to estimate incidence rate ratios (IRR), adjusted for demographics, behaviors, and comorbidities. Results: Over a median follow-up period of 3.5 years (by December 31 st , 2015), 6124 hospitalizations occurred over 19788 person-years (Crude Incidence Rate, 309 per 1000 person-years). Risk of hospitalization increased markedly with lower eGFRcys and higher albuminuria ( Table 1 ). Other baseline comorbidities were also associated with hospitalization risk (IRR [95% CI] for heart failure, coronary heart disease (CHD), stroke, cancer were 1.7 [1.4-2.0], 1.5 [1.3-1.7], 1.3 [1.1-1.6], and 1.2 [0.9-1.5]). Conclusions: Among older adults, both low eGFR and high ACR are strongly related to risk of hospitalization. These findings provide insight for risk stratification and prevention of CKD at older ages. Table 1. Risk of hospitalization by CKD stages defined by eGFR and ACR
Aids to Osteology
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lectures on the Diseases of Infancy and Childhood
Journal: BMJ (1852)

The diseases of the Nervous System are considered in Lectures XI. and XII.Dr West remarks that, to the usual obscurity sur- rounding affections of this class in adult life, special difficulties of investigation are added in the case of children; because in early life locomotive power is not yet acquired, or, if so, may readily be lost again, in the course of ordinary ailments; and further, because children are not able to describe at all, or at least distinctly, the various impairments of sensation which may exist in different parts of the body, or the peculiarities of pain which may be present.The subjects of Irritation, Congestion, and Inflammation of the Substance and Membranes of the Spinal Cord, are illustrated by a series of very interesting cases, on which, however, we cannot stop to remark.Trismus is then considered, but its rarity in this coun- try, and the imperfect evidence in favour of any plan of treatment 1849.]OF INFANCY AND CHILDHOOD.991 hitherto suggested, may excuse us in passing on to the next affec- tion noticed by Dr West, namely, Night Terrors.The occurrence sometimes happens thus :? " A child who has gone to bed apparently well, and has slept soundly for a short time, awakes suddenly in great terror, and with a loud and piercing cry.The child will be found sitting up in its bed, crying out as if in an agony of fear,' Oh dear !Oh dear !take it away !father !mother !' while terror is de- picted on its countenance, and it does not recoguise its parents (who, alarmed by the shriek, have come into its room), but seems wholly occupied with the fearful impression that has aroused it from sleep.By degrees consciousness returns, the child now clings to its mother or nurse, sometimes wants to be taken up and carried about the room, and by degrees, sometimes in ten minutes, sometimes in half-an-hour, it grows quiet, and again falls asleep.As the terror abates, the child in some instances grows quiet at once, but frequently it bursts into a fit of passionate weeping, and sobs itself to rest in its mother's arms.In some instances a quantity of limpid urine is voided as the fit passes off, but this occurrence is by no means constant.Usually, the remainder of the night is passed in tolerably sound sleep, and the following night the child may rest quite undisturbed, or the terrors may again return, and with precisely the same symptoms as before.The attack usually comes on after the child has been from half-an-hour to a couple of hours asleep, and two attacks do not generally occur in the same night.They are always more or less distinctly associated with the impression of some object which occasions alarm,?as a cat or dog, which is fancied to be on the bed ; and this illusion continues even after the child has recognised those around it.The condition is not one of delirium, for the child has no other hallucination; but the attack may return night after night with precisely the same characters."?P. 128.
Gynecologic Radiology
Authors: Wilhelm Z. Stern
Journal: JAMA (1977)

THE PLAIN roentgenogram is the first step in the radiological evaluation of a gynecologic disorder. The bladder should be empty. Displacement of intestinal gas may be the clue to the presence of a pelvic mass. Except for vascular calcification, uterine leiomyoma constitutes the most common cause of pathological pelvic calcification. Subserosal and intramural myomas calcify more frequently than the submucosal variety. The calcification is typically flocculent, patchy, and coalescent (Fig 1), varying in size from tiny punctate deposits to large calcific masses. Occasionally, a uterine myoma may present with arcuate calcification, which must then be differentiated from a cystic lesion or an aneurysm. The plain roentgenogram is often helpful in detecting dermoid cysts of the ovary. About one third of such cysts contain dentigerous elements, thereby permitting a definitive diagnosis. Bone may be identified in about a fourth of the cases, frequently in association with teeth.<sup>1</sup>A circumscribed radiolucent image,
MERS—the latest threat to global health security
Authors: None The Lancet
Journal: The Lancet (2015)

The spread of Middle East respiratory syndrome (MERS) to South Korea, and now to China, is an important signal of the need for increased vigilance in global health security measures. As reported in Correspondence in this week's issue, the rapid transmission of MERS in South Korea led to 12 laboratory-confirmed cases over a 2-week period in May, and many more cases since, with relatives, medical staff, and a fellow patient all contracting the disease, which started with one 68-year-old man who had travelled to the Middle East.
Risk-Adjusted Mortality Rates as a Quality Proxy Outperform Volume in Surgical Oncology—A New Perspective on Hospital Centralization Using National Population-Based Data
Authors: Philip Baum, Jacopo Lenzi, Johannes Diers, Christoph Rust, Martin E. Eichhorn, Samantha Taber, Christoph-Thomas Germer, Hauke Winter, Armin Wiegering
Journal: Journal of Clinical Oncology (2022)

Despite a long-known association between annual hospital volume and outcome, little progress has been made in shifting high-risk surgery to safer hospitals. This study investigates whether the risk-standardized mortality rate (RSMR) could serve as a stronger proxy for surgical quality than volume.We included all patients who underwent complex oncologic surgeries in Germany between 2010 and 2018 for any of five major cancer types, splitting the data into training (2010-2015) and validation sets (2016-2018). For each surgical group, we calculated annual volume and RSMR quintiles in the training set and applied these thresholds to the validation set. We studied the overlap between the two systems, modeled a market exit of low-performing hospitals, and compared effectiveness and efficiency of volume- and RSMR-based rankings. We compared travel distance or time that would be required to reallocate patients to the nearest hospital with low-mortality ranking for the specific procedure.Between 2016 and 2018, 158,079 patients were treated in 974 hospitals. At least 50% of high-volume hospitals were not ranked in the low-mortality group according to RSMR grouping. In an RSMR centralization model, an average of 32 patients undergoing complex oncologic surgery would need to relocate to a low-mortality hospital to save one life, whereas 47 would need to relocate to a high-volume hospital. Mean difference in travel times between the nearest hospital to the hospital that performed surgery ranged from 10 minutes for colorectal cancer to 24 minutes for pancreatic cancer. Centralization on the basis of RSMR compared with volume would ensure lower median travel times for all cancer types, and these times would be lower than those observed.RSMR is a promising proxy for measuring surgical quality. It outperforms volume in effectiveness, efficiency, and hospital availability for patients.